Paul Lapchak, PhD, FAHA is developing natural product analogs to treat acute ischemic stroke. Natural products derived from plants and other natural sources are an untapped resource of bioactive compounds. The emphasis is on polyphenolic compounds based upon fistein and curcuminoid analogs produced by chemical modification of the spice curcumin.
Curcumin derivatives have novel mechanisms of action that can be applied to treat stroke; they also have excellent low-no toxicity profiles.
Lapchak Laboratory is also actively engaged in studies to further the development of transcranial laser therapy to promote recovery of function following a stroke by elucidating the mechanism of action of light therapy. In addition, his laboratory is working to develop new methods to attenuate thrombolytic-induced brain hemorrhage and provide neuroprotection to hemorrhage patients.
Other important projects include:
- Testing neuroprotective agents to attenuate ischemia-induced spinal cord injury and paraplegia
- Testing novel erythropoietin analogs as a treatment for stroke
- Studying the role of cytochrome oxidase in laser-induced neuroprotection
- Developing therapies to use in combination with thrombolytics to treat stroke
- Preliminary testing of cinnamic acid and caffeic acid analogs as neuroprotectants